Pfizer Stock Forecast: Analysts Project Rebound with $32.36 Price Target
Pfizer (PFE) has been assigned a BUY rating by analysts, who have set a price target of $32.36, suggesting a potential upside of 15% from its recent closing price of $28.07. The stock currently offers a dividend yield of 6.19%, which supports the bullish outlook for the company. Pfizer's valuation stands at 10 times forward earnings, significantly lower than its peers Merck (MRK) at 18 times and Bristol Myers Squibb (BMY) at 11 times.
CEO Albert Bourla has consistently exceeded revenue expectations, achieving this in nine out of the last ten quarters. The company has ambitious plans, with 19 pivotal study initiations expected in the coming year across areas such as oncology, obesity, and immunology.
For Your Trading Desk
Sponsor Spike Success.
In the second quarter of 2026, Pfizer reported revenues of $15 billion and an adjusted diluted EPS of 77 cents, while also raising its revenue guidance to between $60.5 billion and $62.5 billion, despite a $4.3 billion writedown that impacted headlines. Year-to-date, Pfizer's shares have increased by 18.58%, reflecting a recovery trend as they approach a 52-week high.
The positive sentiment around Pfizer's stock is bolstered by strong operational growth in launched and acquired products, which saw a 22% increase in Q1 2026. Notably, products like Padcev and Nurtec ODT/Vydura have shown impressive growth rates of 39% and 42%, respectively. The management projects a high single-digit revenue compound annual growth rate (CAGR) from the end of 2028 through 2033.
If the obesity pipeline proves successful, analysts predict a bullish scenario where the stock could reach $36.17 within a year and $52.18 over five years. However, challenges remain, particularly with COVID-related products such as Comirnaty and Paxlovid, which have seen significant revenue declines. The company faces competition from generics and biosimilars, which could reduce revenues by approximately $1.5 billion in 2026.
Despite a 31.44% year-over-year drop in Q1 operating income, some analysts argue this reflects a strategic reinvestment in research and development, with $5.5 billion allocated in the first half of 2026 to support future growth.
Comparatively, Merck's KEYTRUDA has generated substantial sales, and Bristol Myers Squibb shares a similar narrative regarding patent expirations and market positioning. Both companies are seen as key competitors in the pharmaceutical landscape.
Overall, the analysts' price target of $32.36 for Pfizer reflects a high confidence level of 90%, driven by the combination of a solid dividend yield and a promising pipeline. The outlook remains optimistic if the company can maintain its momentum in oncology and obesity while managing the decline of COVID-related products.




